BMT pairs, disease, and transplant characteristics
| Characteristic . | Acute GHVD grade . | P . | |
|---|---|---|---|
| 0 (n = 25) . | I-IV (n = 68) . | ||
| Recipients | |||
| Male, n (%) | 18 (72%) | 36 (53%) | .10 |
| Median age, y (range) | 23 (3-65) | 36 (4-66) | .02 |
| Positive CMV serology | 17 (68%) | 45 (66%) | .87 |
| Underlying diagnosis | |||
| Chronic leukemia | 1 (4%) | 12 (18%) | .17 |
| Acute leukemia | 10 (40%) | 38 (56%) | .17 |
| Other malignant disorders | 4 (16%) | 16 (24%) | .43 |
| Aplasia | 8 (32%) | 1 (1.5%) | < .01 |
| Hemoglobinopathy | 2 (8%) | 1 (1.5%) | .36 |
| Disease status for malignant disorders* | |||
| Early | 10 (67%) | 47 (71%) | .73 |
| Intermediate | 4 (27%) | 13 (20%) | .55 |
| Advanced | 1 (6%) | 6 (9%) | .76 |
| Donors | |||
| Male, n (%) | 19 (76%) | 35 (52%) | .03 |
| Median age, y (range) | 18 (4-60) | 36 (6-68) | .02 |
| Female donor to male recipient | 5 (20%) | 19 (28%) | .44 |
| ABO major incompatibility | 4 (16%) | 7 (10%) | .45 |
| Positive CMV serology | 11 (44%) | 40 (59%) | .20 |
| Transplantation | |||
| Source of cells | |||
| PB | 8 (32%) | 29 (43%) | .35 |
| BM | 17 (68%) | 39 (57%) | .35 |
| Conditioning | |||
| Nonmyeloablative | 7 (28%) | 7 (10%) | .03 |
| TBI-based | 11 (44%) | 34 (50%) | .81 |
| Bu-based | 6 (24%) | 33 (49%) | .03 |
| GVHD prophylaxis | |||
| CSA | 5 (20%) | 4 (6%) | .04 |
| CSA + MTX | 15 (60%) | 61 (90%) | < .01 |
| CSA + others | 5 (20%) | 3 (4%) | .02 |
| Characteristic . | Acute GHVD grade . | P . | |
|---|---|---|---|
| 0 (n = 25) . | I-IV (n = 68) . | ||
| Recipients | |||
| Male, n (%) | 18 (72%) | 36 (53%) | .10 |
| Median age, y (range) | 23 (3-65) | 36 (4-66) | .02 |
| Positive CMV serology | 17 (68%) | 45 (66%) | .87 |
| Underlying diagnosis | |||
| Chronic leukemia | 1 (4%) | 12 (18%) | .17 |
| Acute leukemia | 10 (40%) | 38 (56%) | .17 |
| Other malignant disorders | 4 (16%) | 16 (24%) | .43 |
| Aplasia | 8 (32%) | 1 (1.5%) | < .01 |
| Hemoglobinopathy | 2 (8%) | 1 (1.5%) | .36 |
| Disease status for malignant disorders* | |||
| Early | 10 (67%) | 47 (71%) | .73 |
| Intermediate | 4 (27%) | 13 (20%) | .55 |
| Advanced | 1 (6%) | 6 (9%) | .76 |
| Donors | |||
| Male, n (%) | 19 (76%) | 35 (52%) | .03 |
| Median age, y (range) | 18 (4-60) | 36 (6-68) | .02 |
| Female donor to male recipient | 5 (20%) | 19 (28%) | .44 |
| ABO major incompatibility | 4 (16%) | 7 (10%) | .45 |
| Positive CMV serology | 11 (44%) | 40 (59%) | .20 |
| Transplantation | |||
| Source of cells | |||
| PB | 8 (32%) | 29 (43%) | .35 |
| BM | 17 (68%) | 39 (57%) | .35 |
| Conditioning | |||
| Nonmyeloablative | 7 (28%) | 7 (10%) | .03 |
| TBI-based | 11 (44%) | 34 (50%) | .81 |
| Bu-based | 6 (24%) | 33 (49%) | .03 |
| GVHD prophylaxis | |||
| CSA | 5 (20%) | 4 (6%) | .04 |
| CSA + MTX | 15 (60%) | 61 (90%) | < .01 |
| CSA + others | 5 (20%) | 3 (4%) | .02 |
BMT indicates bone marrow transplantation; BM, bone marrow; Bu, busulfan; CMV, cytomegalovirus; CSA, cyclosporin A; GVHD, graft-versus-host disease; MTX, methotrexate; PB, peripheral blood; TBI, total body irradiation; and y, year.
Bittencourt et al.17